



Paclitaxel 80, Breast Cancer, adjuvant

Protocol-ID: 581 V1.2 (Basic), PACL80, Breast Ca, adj.

Indication(s)

- Breast Cancer; ICD-10 C50.-

Cycles

Cycle length 7 days, recommended cycles: 12

Protocol sequences

- [EC \(EPIR90/CYCL600\), Breast Ca, adj. \(PID579\) -|- PACL80, Breast Ca, adj. \(PID581\)](#)
- [EC \(EPIR90/CYCL600\), Breast Ca, adj., dd \(PID2702\) -|- PACL80, adj. \(PID581\)](#)
- [SWOG S0221: AC \(DOXO60/CYCL600\), Breast Ca, adj., dd, var. 1 \(PID478\) -|- PACL80, adj. \(PID581\)](#)
- [AC \(DOXO60/CYCL600\), Breast Ca, adj. \(PID599\) -|- PACL80, adj. \(PID581\)](#)

References

- Sparano JA, Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008 Apr 17;358(16):1663-71. doi: 10.1056/NEJMoa0707056. PMID: 18420499. [[PMID](#)]
- De Laurentiis M, Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008 Jan 01;26(1):44-53. doi: 10.1200/JCO.2007.11.3787. PMID: 18165639. [[PMID](#)]
- Budd GT, SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 2015 Jan 01;33(1):58-64. doi: 10.1200/JCO.2014.56.3296. PMID: 25422488. [[PMID](#)]
- Shulman LN, Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol 2014 Aug 01;32(22):2311-7. doi: 10.1200/JCO.2013.53.7142. PMID: 24934787. [[PMID](#)]

Recommendations

- 08/2019: [European Society for Medical Oncology](#)
- 03/2023: [National Comprehensive Cancer Network](#)

Links

- One-hour paclitaxel infusions: review of safety and efficacy. [[PMID](#)]

Important notice

The copyrighted protocols are treatment recommendations. The information contained in this compilation on cytostatic drugs, concomitant medication and other therapeutic procedures, as well as dosage and application information, is continuously reviewed with all due care by the authors and editors involved. Nevertheless, the publishers and authors do not assume any liability for the correctness - also with regard to possible printing errors.

The protocols may not be changed in terms of content.

Diagnosis, indication for therapy and treatment of malignant diseases must be carried out in each individual case by the hematologist and oncologist on his or her own responsibility. The treating physician is obligated to this personal responsibility to weigh in each case before a diagnostic or therapeutic measure, indication, contraindications, dosage and application under consideration of the specialized information or other documents of the manufacturers. This applies in particular to rarely used preparations or preparations that are new to the market.



The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

